Does Caspase-6 Have a Role in Perinatal Brain Injury?

Ana A. Baburamani a, b, Yasuka Miyakuni b, c, Regina Vontell b, Veena G. Supramaniam b, Pernilla Svedin a, Mary Rutherford b, Pierre Gressens b, d, e, Carina Mallard a, Satoru Takeda c, Claire Thornton b, Henrik Hagberg a, b

a Perinatal Center, Institute of Neuroscience and Physiology, Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; b Centre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St. Thomas’ Hospital, London, UK; c Department of Obstetrics and Gynaecology, Faculty of Medicine, Juntendo University, Tokyo, Japan; d INSERM, U1141, and e University Paris Diderot, Sorbonne Paris Cité, UMRS 1141, Paris, France

Key Words
Caspase-6 · Hypoxia-ischaemia · Q-VD-OPh · Lipopolysaccharide · Microglia

Abstract
Apoptotic mechanisms are centre stage for the development of injury in the immature brain, and caspases have been shown to play a pivotal role during brain development and in response to injury. The inhibition of caspases using broad-spectrum agents such as Q-VD-OPh is neuroprotective in the immature brain. Caspase-6, an effector caspase, has been widely researched in neurodevelopmental disorders and found to be important following adult stroke, but its function in the neonatal brain has yet to be detailed. Furthermore, caspases may be important in microglial activation; microglia are required for optimal brain development and following injury, and their close involvement during neuronal cell death suggests that apoptotic cues such as caspase activation may be important in microglial activation. Therefore, in this study we aimed to investigate the possible apoptotic and non-apoptotic functions caspase-6 may have in the immature brain in response to hypoxia-ischaemia. We examined whether caspases are involved in microglial activation. We assessed cleaved caspase-6 expression following hypoxia-ischaemia and conducted primary microglial cultures to assess whether the broad-spectrum inhibitor Q-VD-OPh or caspase-6 gene deletion affected lipopolysaccharide (LPS)-mediated microglial activation and phenotype. We observed cleaved caspase-6 expression to be low but present in the cell body and cell processes in both a human case of white matter injury and 72 h following hypoxia-ischaemia in the rat. Gene deletion of caspase-6 did not affect the outcome of brain injury following mild (50 min) or severe (60 min) hypoxia-ischaemia. Interestingly, we did note that cleaved caspase-6 was co-localised with microglia that were not of apoptotic morphology. We observed that mRNA of a number of caspases was modulated by low-dose LPS stimulation of primary microglia. Q-VD-OPh treatment and caspase-6 gene deletion did not affect microglial activation but modified slightly the M2b phenotype response by changing the time course of SOCS3 expression after LPS administration.

A.A.B. and Y.M. share first authorship. C.T. and H.H. share senior authorship.

© 2015 S. Karger AG, Basel
0378–5866/15/0375–0321$0.00/0
www.karger.com/dne

This is an Open Access article licensed under the terms of the Creative Commons Attribution 3.0 Unported license (CC BY 3.0) (www.karger.com/OA-license-WT), applicable to the online version of the article only.

Dr. Ana A. Baburamani
Centre for the Developing Brain, Department of Perinatal Imaging and Health
Division of Imaging and Biomedical Engineering, Kings College London
1st Floor South Wing, St. Thomas’ Hospital, London SE1 7EH (UK)
E-Mail ana.baburamani@kcl.ac.uk
tion. Our results suggest that the impact of active caspase-6 in the developing brain is subtle, and we believe there are predominantly other caspases (caspase-2, -3, -8, -9) that are essential for the cell death processes in the immature brain.

© 2015 S. Karger AG, Basel

Introduction

The immature brain has a high expression of many pro-apoptotic genes in comparison with the adult [for a summary, see 1–3]. Consequently, the activation of apoptotic pathways, particularly caspase activation, following hypoxia-ischaemia has been shown to play a pivotal role in the cell death process [4]. Caspases are cysteine-dependent aspartate proteases that, following activation, regulate apoptosis and inflammation and, more recently, have been reported to have non-apoptotic functions [5]. Caspases can be sub-classified into initiator (caspase-2, -8, -9, -10), effector (caspase-3, -6, -7) and inflammatory (caspase-1, -4 [human], -5, -11 [rodent]). In the developing brain, initiator caspase-2 and effector caspase-3 are abundantly expressed and robustly activated following hypoxia-ischaemia [6–8]. Directly targeting specific caspases or broad-spectrum inhibition of caspases using Q-VD-OPh has been shown to be protective in rodent models of hypoxic-ischaemic injury [8–12].

Although classically defined as an effector caspase with homology to caspase-3, studies show that caspase-6 can activate caspase-3 [13], suggesting it may be important in the neonatal brain where caspase-3 is so highly expressed. Recently, Simon et al. [14] reported that caspase-3 can also activate caspase-6 in the process of axonal degeneration, suggesting a dichotomous interaction between these caspases. Whilst pro-caspase-6 expression is low in the fetal and adult human brain [15], caspase-6 has been shown to be crucial in neurodegenerative disorders such as Huntington’s, Alzheimer’s and Parkinson’s disease [16, 17], in age-related memory decline [18], following adult stroke [19], and in hippocampal epileptogenesis and epilepsy [20]. From studies in the adult brain, caspase-6 mRNA was upregulated in the ipsilateral cortex within 6 h following focal cerebral ischaemia [21]. Following adult stroke, caspase-6 knockout mice appeared to be protected, with reduced axonal degeneration and an improvement in functional outcome [19]. What function caspase-6 has in the developing brain and its role in immature brain injury remains to be investigated.

Developmentally and following injury, neuronal cell death occurs via apoptosis, and it is microglia, the resident phagocytic cells of the brain, that are involved in both the initiation of cell death and phagocytosing dead and dying neurons [22, 23]. This suggests that there could be a tightly regulated interaction between apoptotic cues such as caspase activation and microglial activation. Burguillos et al. [24] have shown that caspase-8 and caspase-3/7 signalling were required for the activation of microglia and, more recently, extracellular caspase-6 was seen to enhance microglial production of TNF-α, regulating inflammatory pain and synaptic plasticity [25]. These studies highlight that greater understanding is required to define the interaction between caspases and microglia.

In this study we investigated the possible apoptotic and non-apoptotic functions caspase-6 may have in the immature brain. First we assessed the spatio-temporal expression and possible contribution of activated (cleaved) caspase-6 following neonatal hypoxia-ischaemia in the development of brain injury. Secondly, we examined the non-apoptotic roles of caspases in inflammatory processes, more specifically, whether the neuroprotective effects that Q-VD-OPh elicits are mediated by modulating microglial activation and to what extent caspase-6 may be involved in microglial activation.

Materials and Methods

Human Post-Mortem Case

Informed parental consent was acquired according to the National Health Services UK guidelines, and study ethics were obtained from the National Research Ethics Services (West London, UK (ethics number, 07/H0707/139; Post-Mortem Magnetic Imaging Study of the Developing Brain). The case examined was a pre-term post-mortem brain (gestational age at birth 24 weeks, postnatal age 36 days, post-menstrual age 29.1 weeks) with evidence of white matter injury on post-mortem MRI and histopathology assessment at autopsy.

Animals

Mice and rats were bred in-house, kept in a 12-hour light/dark cycle and fed a standard laboratory chow diet and drinking water ad libitum (Experimental Biomedicine, University of Gothenburg, Sweden). All animal experimentation was conducted in accordance with the Department of Agriculture (Jordbruksverket, Sweden) and approved by the Gothenburg animal ethics committee.

Genetically Modified Animals

Caspase-6 heterozygote (Het; +/-) mice were purchased from the Jackson Laboratory (cryopreserved stock No. 006236, B6.129S6-Casp6tm1Flv/J) [26, 27]. Caspase-6 Het mice were bred together to get mixed genotypes – caspase-6 knockout (KO; +/-), caspase-6 Het and caspase-6 wild type (WT; +/-). Mixed litters were used for hypoxia-ischaemia experiments.
Induction of Hypoxia-Ischaemia in Neonatal Mice and Rats

Post-natal day 9 (P9) mice were subjected to unilateral hypoxia-ischaemia, essentially according to the Rice-Vannucci model [6, 28, 29]. This model results in a focal ischaemic injury allowing for a comparison between the injured (ipsilateral) and the non-injured (contralateral) hemisphere. Both female and male pups were used. Briefly, the mice were anaesthetised with isoflurane (4.5% for induction and 2% for maintenance) in a mixture of nitrogen (97%) and oxygen (3%) for 50 min (mild hypoxia). Brains were collected at 8, 24 and 72 h following hypoxia-ischaemia and in controls.

Immunohistochemistry

Immunohistochemical analysis was performed in both a human tissue sample and our animal studies to determine the protein expression of cleaved caspase-6 (cl-C6) or cleaved caspase-3 (cl-C3) at 8, 24 and 72 h after hypoxia-ischaemia and in controls. Immunohistochemical staining was performed as previously described [30] for the detection of cl-C6 using rabbit anti-cl-C6 (1:500; No. 9761; Cell Signaling, Hertfordshire, UK); for the cl-C3 (1:500; No. 9671; Cell Signaling, Hertfordshire, UK); for the detection of cl-C6 using rabbit anti-cl-C6 (1:500; No. 9671; Cell Signaling) and biotinylated goat anti-rabbit IgG secondary antibody (15 μg/ml; Vector Laboratories). As negative controls, we performed staining in the absence of the primary antibodies and pre-absorption with the recombinant caspase-6 (1 U; Enzo Life Sciences; Exeter, UK); no specific staining was identified in these preparations.

Brain Injury Assessment

Pups (caspase-6 WT, Het and KO) were killed and perfused intracardially with 0.9% physiological saline followed by 5% buffered formaldehyde (Histolab AB, Sweden). After dehydration through graded ethanol and xylene (X-TRA-Solv, Dalab, Sweden), brains were paraffin-embedded and serially cut into 7-μm coronal sections on Superfrost™ Plus slides (Thermo Scientific, Sweden) with every 50th section stained. To evaluate brain injury, sections were incubated with antibodies for microtubule-associated protein-2 (MAP-2), a neuronal marker expressed in neurons and dendrites, and myelin basic protein (MBP), a major constituent of the myelin sheath of oligodendrocytes where loss of staining indicated infarcted areas and MBP-associated white matter loss, respectively. Briefly, sections were dehydrated and underwent antigen retrieval with 0.01 M citric acid buffer (pH 6.0; 10 min heat, 20 min cool), peroxidase blocking with 3% H₂O₂ in PBS for 5 min and incubated with biotinylated Ly-sepersicon esculentum (tomato) lectin (1:1,000; Vector Laboratories) and followed with streptavidin-conjugated Alexa Fluor 488 (Vector Laboratories).

Brain Injury Assessment

The total image was acquired using the CM1 and CM2 modules for virtual tissue scan (MicroBrightField, Inc., Colchester, VT, USA). The sections were examined under bright-field microscopy using a light microscope (DM6000 B; Leica Microsystems Ltd., Milton Keynes, UK) equipped with a motorised specimen stage for automated sampling. CCD colour video camera and stereology software (Stereo Investigator, v8.27; MicroBrightField, Inc.). The average area of each contour was encompassed by an average area of 1.0 mm² to provide a scanned image collected using a 40× objective (0.0426 mm²).

Immunofluorescence Double-Labelling

To identify the protein expression of cl-C6, double-labelling immunofluorescence was performed using a cocktail of rabbit anti-cl-C6 (1:500) with a monoclonal antibody specific for either astrocytes (GFAP, 1:1,000; Sigma-Aldrich) or oligodendrocytes (Olig2, 1:2,000; Millipore, Temecula, Calif., USA) and a secondary antibody cocktail consisting of goat anti-mouse IgG conjugated to Alexa Fluor 488 (4 μg/ml; Invitrogen, Eugene, Oreg., USA) and goat anti-rabbit IgG conjugated to Alexa Fluor 546 (4 μg/ml; Invitrogen). Immunofluorescence was performed as previously described [30].

For double-labelling with cl-C6 and the microglia we stained cl-C6 with Alexa Fluor 546. The slides were then immersed in 4% paraformaldehyde for 5 min and incubated with biotinylated Ly-sepersicon esculentum (tomato) lectin (1:1,000; Vector Laboratories) and followed with streptavidin-conjugated Alexa Fluor 488 (Vector Laboratories).

Image Acquisition

The total image was acquired using the CM1 and CM2 modules for virtual tissue scan (MicroBrightField, Inc., Colchester, VT, USA). The sections were examined under bright-field microscopy using a light microscope (DM6000 B; Leica Microsystems Ltd., Milton Keynes, UK) equipped with a motorised specimen stage for automated sampling. CCD colour video camera and stereology software (Stereo Investigator, v8.27; MicroBrightField, Inc.). The average area of each contour was encompassed by an average area of 1.0 mm² to provide a scanned image collected using a 40× objective (0.0426 mm²).

Brain Injury Assessment

Pups (caspase-6 WT, Het and KO) were killed and perfused intracardially with 0.9% physiological saline followed by 5% buffered formaldehyde (Histolab AB, Sweden). After dehydration through graded ethanol and xylene (X-TRA-Solv, Dalab, Sweden), brains were paraffin-embedded and serially cut into 7-μm coronal sections on Superfrost™ Plus slides (Thermo Scientific, Sweden) with every 50th section stained. To evaluate brain injury, sections were incubated with antibodies for microtubule-associated protein-2 (MAP-2), a neuronal marker expressed in neurons and dendrites, and myelin basic protein (MBP), a major constituent of the myelin sheath of oligodendrocytes where loss of staining indicated infarcted areas and MBP-associated white matter loss, respectively. Briefly, sections were dehydrated and underwent antigen retrieval with 0.01 M citric acid buffer (pH 6.0; 10 min heat, 20 min cool), peroxidase blocking with 3% H₂O₂ in PBS for 10 min, serum blocking with 4% horse serum and overnight incubation at 4°C with either MAP-2 (1:1,000, Sigma-Aldrich, USA) or MBP (SMI-94, 1:10,000, Sternberger Monoclonal Inc., USA). Sections were then incubated for 1 h at room temperature with secondary antibody (horse anti-mouse, 1:250; Vector Laboratories, USA) followed by incubation for 1 h with avidin-biotin complex (Vector Laboratories, USA) and visualised with 3,3′-diaminobenzidine (DAB). Positive-stained areas were measured using the Olympus Micro Image analysis software system (V4.0, Olympus Optical, Tokyo, Japan).

Loss of MAP-2 and MBP staining was determined by subtracting the MAP-2- or MBP-positive area in the ipsilateral hemisphere from the contralateral hemisphere; values are expressed as a percentage of tissue loss from the contralateral hemisphere. Total volume loss was calculated according to the Cavalieri’s principle:

Does Caspase-6 Have a Role in Perinatal Brain Injury?

Dev Neurosci 2015;37:321–337
DOI: 10.1159/000375368
V = ΣA × P × T, where V = total volume, ΣA = sum of the areas, P = the inverse of the section's sampling fraction, and T = section thickness. MBP staining was measured in the subcortical white matter region at one level of the brain (approximately at the level of bregma −2.12 mm) [31].

**Primary Microglial Cultures**

Primary mixed glial cultures were prepared from P1 to P3 C57Bl/6 (WT) and caspase-6 KO mice of both sexes, as previously described [32], with some alterations. Briefly, brains were isolated and the cerebellum removed and washed in cold Hank's buffered salt solution (Sigma-Aldrich, USA) supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, USA). Forebrains were gently dissociated by trituration in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS; Gibco; Life Technologies Sweden) and 1% antibiotics. The cell suspension was passed through a 70-μm filter (Becton-Dickinson) and plated in 75-cm² flasks with vented caps (Sarstedt, Germany) at a density of two brains per flask. After 7 days all the media was replaced with DMEM/10% FBS/antibiotics and cultured for a further 7 days. Microglia were then detached by shaking (250 rpm, for 3 h at 36°C) on a rotary shaker, and the microglia cell suspension was collected and centrifuged (250 g × 10 min). The media were then removed, the pellet was resuspended in DMEM/2% FBS/antibiotics and the number of cells were counted with an automated cell counter (Scepter; Millipore) and seeded into 12-well plates (approximately 2–2.5 × 10⁵ cells per well). Flasks and plates were incubated in a humidified oven at 37°C containing 5.1% CO₂ in air.

In vitro Lipopolysaccharide and Q-VD-OPH Stimulation

After 24 h, the cell culture medium was replaced with DMEM/antibiotics. WT and caspase-6 KO primary microglial cells were stimulated with 10 ng/ml (diluted in sterile water) of *Escherichia coli* lipopolysaccharide (LPS; 055:B5; List Biological Laboratories, USA) or sterile water (control) – each 12-well plate always contained both treatments. We treated WT microglia with the broad-spectrum caspase inhibitor Q-VD-OPH (20 μM; diluted in DMSO; SM Biochemicals, USA) immediately prior to LPS stimulation. The dose of Q-VD-OPH was chosen based on the manufacturer’s suggestions. Each 12-well plate in these experiments contained all treatments: control (DMSO + sterile water), LPS (DMSO + LPS 10 ng/ml), Q-VD-OPH only, and Q-VD-OPH + LPS. We also treated cells with negative control (Q-VE-OPH, 20 μM; SM Biochemicals, USA), which were also included on each plate (Q-VE-OPH only, Q-VE-OPH + LPS) – these data are not shown in this manuscript. The entire culture medium was collected (1 ml) at 6, 24 or 48 h; 300 μl was used immediately for a lactate dehydrogenase assay (Roche, USA) and the remaining supernatant stored at −80°C until further analysis. Cells were washed with RNAse-free PBS and then lysed with 350-μl buffer RLT (Qiagen; containing β-mercaptoethanol at a concentration of 1:100), harvested and stored at −80°C for gene expression analysis. All time points were run in each independent experiment and all group experiments were performed a minimum of 3–6 independent times.

Cytokine/Chemokine Assay

Cytokines and chemokines were measured in cell supernatants (50 μl) from primary microglia cultures using a Bio-Plex Pro mouse cytokine 23-plex assay (Bio-Rad, Sweden), following the manufacturer’s protocol. Concentrations of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17a, eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-γ), KC/chemokine (C-X-C motif) ligand 1 (CXCL1), monocyte chemotactic protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2), macrophage inflammatory protein 1α (MIP-1α)/CCL3, MIP-1β/CCL4, RANTES, and TNF-α were simultaneously detected on a BioPlex 200 System (Bio-Rad, Sweden). For some cytokines the values were too low or too high for accurate detection; if this occurred for 3 or more samples, no value was calculated.

RT-qPCR

Total RNA from primary microglial cell was extracted with RNaseasy micro kit (Qiagen, Sweden), following the manufacturer’s instructions. RNA concentration and purity (260/280 ratio) were quantified spectrophotometrically with a NanoDrop (ND-1000 UV/Vis Spectrophotometer; Thermo Scientific, USA). A Quantitect reverse transcription kit (Qiagen, Sweden) was used to synthesise first-strand cDNA from 75 ng of total RNA, following the manufacturer’s instructions. RT-qPCR was performed in duplicate, with each PCR containing 2 μl cDNA, 10 μl QuantiFast SYBR Green PCR Kit (Qiagen, Sweden), 2 μl PCR Primer assay (Qiagen, Sweden), and 6 μl H₂O. The amplification protocol comprised an initial 5-min denaturation at 95°C followed by 45 cycles of denaturation at 95°C for 10 s and annealing/extension for 30 s at 60°C on a LightCycler 480 (Roche, Sweden). Melt curve analysis was performed to ensure that only one PCR product was obtained. A standard curve was also generated using increasing concentrations of cDNA, allowing for quantification and estimating amplification efficiency. Amplification transcripts were quantified with the relative standard curve and normalised against reference gene YWHAZ. Comparison of reference genes YWHAZ, GAPDH, GUSB, and 18S was done for all treatments, genotypes and time points using GenEx Software (v5.1.1.1; MultiD Analyses AB, Sweden), which uses GeNorm and NormFinder algorithms to calculate optimal reference genes. All primer details are listed in table 1.

**Data Analysis**

Data are expressed as mean ± SEM. All primary microglia culture experiments were conducted a minimum of 3 independent times. All statistical analyses were performed using GraphPad Prism 6 Software (GraphPad Software, San Diego, Calif., USA), with significance set at p < 0.05. All data were assessed for normality. Brain injury analysis was conducted using a one-way ANOVA. Gene expression and multiplex measurements were assessed with a two-way ANOVA for treatment and time. If significant, a Dunnett’s (comparing with control or WT LPS) or Sidak post hoc (more power than Bonferroni) analysis was conducted.

**Results**

**Expression of cl-C6 in Human Preterm White Matter Injury**

In order to begin assessing the importance of caspase-6 activity in neonatal brain injury, we investigated...
whether cl-C6 could be seen in human post-mortem preterm brain sections where white matter injury had occurred. We identified cl-C6 immunostaining (a marker for caspase-6 activation) in fine fibrous (fig. 1 Ai, Aii) and perinuclear cells (fig. 1 Bi) in the periventricular white matter (fig. 1 A) and anterior limb of the internal capsule (fig. 1 B), respectively. Caspase-3 has been shown to be activated (cl-C3) within 24 h following hypoxia-ischaemia [33]. This post-mortem case had a post-menstrual age of 29.1 weeks (born at a gestational age of 24 weeks) and, in the same regions examined, showed regions of sporadic cl-C3-positive staining (fig. 1 C, D).

Active Caspase-6 Was Identified in Microglia in the White Matter
To identify the cell types that expressed cl-C6 in white matter we utilised double-labeling immunofluorescence of cl-C6 antibody with glial markers for microglia (tomato lectin; fig. 1G), astroglia (GFAP; fig. 1H) and oligodendrocytes (Olig-2; fig. 1I). Double-label immunofluorescence revealed that cl-C6-positive cells were co-localised with microglia but not with astrocytes or oligodendrocytes. There is no single reported marker of activated microglia; therefore, we closely inspected the

Table 1. Primers used for qPCR

| Gene   | NCBI ID                        | EntrezGene ID | Primer       | QuantiTect primer set | Amplified exons | Amplicon length, bp |
|--------|--------------------------------|---------------|--------------|-----------------------|----------------|---------------------|
| YWHAZ  | NM_001253805 (3,604 bp)         | 22631         | Mm_Ywhaz_1_SG | QT00105350            | 3/4            | 99                  |
|        | NM_001253806 (3,329 bp)         |               |              |                       |                |                     |
|        | NM_001253807 (3,160 bp)         |               |              |                       |                |                     |
|        | NM_011740 (3,801 bp)            |               |              |                       |                |                     |
| Caspases |                               |               |              |                       |                |                     |
| Caspase-1 | NM_009807 (1,533 bp)          | 12362         | Mm_Casp1_1_SG | QT00199458            | 6/7            | 101                 |
| Caspase-2 | NM_007610 (3,463 bp)          | 12366         | Mm_Casp2_1_SG | QT00108745            | 1/2            | 81                  |
| Caspase-3 | NM_009810 (1,466 bp)          | 12367         | Mm_Casp3_2_SG | QT01164779            | 3/4/5          | 150                 |
| Caspase-4 | NM_007609 (1,433 bp)          | 12363         | Mm_Casp4_1_SG | QT00096117            | 6/7            | 81                  |
| Caspase-5 | NM_009811 (1,455 bp)          | 12368         | Mm_Casp5_2_SG | QT00494921            | 6/7            | 125                 |
| Caspase-6 | NM_009812 (2,585 bp)          | 12369         | Mm_Casp6_1_SG | QT01058085            | 2/3            | 135                 |
| Caspase-7 | NM_001080126 (2,412 bp)       | 12370         | Mm_Casp8_1_SG | QT00171437            | 7/8            | 74                  |
| Caspase-8 | NM_001277926 (2,528 bp)       | 12371         | Mm_Casp9_1_SG | QT00133280            | 5/6/7          | 189                 |
| Caspase-9 | NM_015733 (3,896 bp)          | 12371         | Mm_Casp9_1_SG | QT00133280            | 5/6/7          | 189                 |

Microglial phenotype

| Gene            | NCBI ID                        | EntrezGene ID | Primer       | QuantiTect primer set | Amplified exons | Amplicon length, bp |
|-----------------|--------------------------------|---------------|--------------|-----------------------|----------------|---------------------|
| COX2 (Ptgs)     | NM_011198 (4,150 bp)           | 19225         | Mm_Ptgs2_1_SG | QT00165347            | 5/6            | 95                  |
| iNOS (NOS2)     | NM_010927 (3,990 bp)           | 18126         | Mm_Nos2_2a_1_SG | QT01535800           | 3/4            | 131                 |
| IGF-1           | NM_001111274 (7,039 bp)        | 16000         | Mm_Igf1_1_SG | QT00154469            | 3/4            | 114                 |
| CD206 (MRC)     | NM_0086255 (3,322 bp)          | 17533         | Mm_Mrc1_1_SG | QT00103012            | 28/29/30       | 132                 |
| SOCS3           | NM_007707 (2,742 bp)           | 12702         | Mm_Socs3_3_SG | QT02488990            | 90             |                     |
| IL-1ra          | NM_00139701 (2,480 bp)         | 16181         | Mm_Il1rn1_1_SG | QT0096054             | 2/3/4          | 116                 |
|                 | NM_001159562 (2,409 bp)        |               |              |                       |                |                     |
|                 | NM_031167 (2,464 bp)           |               |              |                       |                |                     |

cl-C6 Is Expressed Following Neonatal Hypoxia-Ischaemia in the Rat Brain
To investigate the temporal expression and localisation of cl-C6, we used the well-characterised Vannucci model of hypoxic-ischaemic injury [28]. We performed immunohistochemistry for cl-C6 in control (P8) rat brain sections as well as sections taken at 8, 24 and 72 h following hypoxia-ischaemia. We detected sporadic cl-C6 immunostaining in white matter 72 h after hypoxia-ischaemia in both the ipsilateral (fig. 1E) and contralateral hemispheres (fig. 1F). In the cortex (fig. 1Ei), cl-C6 reactivity was detected in the damaged axonal processes on the ipsilateral side but not in axonal processes of the contralateral side.

Active Caspase-6 Was Identified in Microglia in the White Matter
To identify the cell types that expressed cl-C6 in white matter we utilised double-labelling immunofluorescence of cl-C6 antibody with glial markers for microglia (tomato lectin; fig. 1G), astroglia (GFAP; fig. 1H) and oligodendrocytes (Olig-2; fig. 1I). Double-label immunofluorescence revealed that cl-C6-positive cells were co-localised with microglia but not with astrocytes or oligodendrocytes. There is no single reported marker of activated microglia; therefore, we closely inspected the
morphology of positively stained microglia. The somatic cl-C6 immunoreactivity that co-localised with the tomato lectin appeared to be present only in amoeboid-shaped cells, which is more indicative of activated microglia – interestingly, these cells did not appear to be of apoptotic morphology. We also observed Iba-1-positive microglia co-localising with cl-C6 at 72 h following hypoxia-ischaemia in WT mice (data not shown).

Cascade Response of Caspase-3 Expression Is Seen Following Neonatal Hypoxia-Ischaemia in the Rat Brain
cl-C3 is robustly upregulated in neonatal hypoxia-ischaemia [33] and is indicative of apoptotic changes occurring in the cell – identified by somatic blebbing or fragmentation. We compared the expression of cl-C6 with cl-C3 in the same tissue and found that ipsilateral hemisphere (fig. 1) cortical regions were abundant with cl-C3 nuclear expression that extended into cell processes 72 h following hypoxia-ischaemia. This was particularly evident in the cortical region where punctate and fragmented staining was seen amongst the cl-C3-positive nuclei. Beneath the core of the infarcted area in the white matter region cl-C3 expression was both nuclear and fibrous. However, in the contralateral side (fig. 1K) the expression was in sporadic nuclei in both the cortical and white matter regions, but the fine punctate immunoreactivity in the processes was not present.

Neuropathology Outcome in Caspase-6 Knockout Mice Following Hypoxia-Ischaemia
Mixed litters were randomly subjected to either 50 min (WT, n = 16, 7 males, 9 females; Het, n = 25, 13 males, 12 females; KO, n = 22, 11 males, 11 females) or 60 min (WT, n = 18, 11 males, 7 females; Het, n = 26, 13 males, 13 females; KO, n = 18, 10 males, 8 females) of hypoxia-ischaemia. Brain Injury Evaluation
Brain injury was assessed 72 h following 50 or 60 min of hypoxia-ischaemia in 7 levels of the brain (level 1 corresponding to the posterior brain). There was no significant difference between genotypes (WT, Het or KO) following 50 min of hypoxia-ischaemia (fig. 2A). At the posterior level of the brain (level 1) there was a significant (p = 0.05) difference between genotypes, where Het mice showed greater injury (57.12 ± 4.59%) compared with WT (42.52 ± 4.01%), but there was no significant difference at any other levels analysed (fig. 2B). There was also no significant difference in the volume of tissue loss following 50 min (fig. 2C) or 60 min (fig. 2D) of hypoxia-ischaemia.

Subcortical White Matter Loss
Injury to the subcortical white matter at the level of the hippocampus was assessed using MBP immunohistochemistry. Gene deletion of caspase-6 did not have any significant effect on loss of white matter following 50 min (fig. 2E) or 60 min (fig. 2F) of hypoxia-ischaemia.

Caspase Expression in Primary Microglia
Alterations in Caspase Gene Expression in Primary Microglia Following LPS Stimulation
As our previous results suggested that caspase-6 may play a role in activated microglia, we assessed which caspases were present in primary microglia and determined whether stimulation with low-dose LPS (10 ng/ml) would modulate their expression. We found microglial expression of all caspases measured and significant treatment effects were seen for mRNA expression of caspase-2 (fig. 3A, p < 0.001), caspase-3 (fig. 3D, p < 0.01), caspase-6 (fig. 3E, p < 0.0001), caspase-1 (fig. 3G, p < 0.05), and caspase-11 (fig. 3H, p < 0.0001). Post hoc analysis revealed that mRNA expression of caspase-2 (an initiator caspase) and caspase-6 (an effector caspase) was significantly downregulated following LPS stimulation. In contrast,
the expression of caspase-11 (an inflammatory caspase) was upregulated at 6, 24 and 48 h following LPS stimulation. No differences were seen in caspase-8 (fig. 3B), caspase-9 (fig. 3C) or caspase-7 (fig. 3F).

To check the efficacy of the pan-caspase inhibitor Q-VD-OPh (20 μm) and/or LPS (10 ng/ml) on caspase activity in primary microglia we used Caspase-Glo® (Promega, USA; as per manufacturer’s instructions on 4 independent experiments) substrates 3/7 (Z-DEVD), 6 (Z-VEID) and 8 (Z-LETD) at 6, 24 and 48 h after treatment. Caspase activity was not influenced by low-dose administration of the pro-inflammatory TLR-4 agonist LPS. Caspase-3/7 (by 95%), caspase-8 (by 92%) and caspase-6 (by 57%) were all substantially reduced at 48 h after treatment with the
broad-spectrum inhibitor Q-VD-OPh (data not shown). The data demonstrate that the dose of Q-VD-OPh was sufficient to reduce microglial caspase activity, but the relative contribution of the different caspases remains unclear because of the overlap in specificity of the substrates used [34–36]. We also conducted lactate dehydrogenase measurements, an assessment of cell membrane integrity, on cell supernatants and found no difference across time or between treatment groups (data not shown), suggesting that the dose of LPS and the administration of Q-VD-OPh had no effect on microglial viability.

**Cytokine and Chemokine Expression Following Microglial Stimulation with Q-VD-OPh and Caspase-6 KO**

To determine the effect of caspase-6 activity on microglial activation and phenotype we prepared primary microglial cultures from caspase-6 KO mice and measured cytokines and phenotypic markers. As caspase-3/7 and caspase-8 signalling has been reported to mediate microglial activation [24], we compared the caspase-6 KO microglia with WT microglia treated with Q-VD-OPh.

---

**Fig. 3.** Caspase mRNA in primary microglia following LPS (10 ng/ml). Gene expression for the following caspases was assessed in WT primary microglia: initiator – caspase-2 (A), caspase-8 (B) and caspase-9 (C); effector – caspase-3 (D), caspase-6 (E) and caspase-7 (F), and inflammatory – caspase-1 (G) and caspase-11 (H). LPS-treated microglia (black bars) were normalised and compared with control (white bars) cells for each time point. Data were analysed with a two-way ANOVA (for time and treatment) and, when significant, a Sidak post hoc analysis was conducted. Data are mean ± SEM (n = 5 independent experiments). * p < 0.05, ** p < 0.01.
### Table 2. Multiplex analysis of microglial cell supernatants

| Analyte       | Treatment               | 6 h         | 24 h         | 48 h         |
|---------------|-------------------------|-------------|--------------|--------------|
| **IL-1α**     | Control                 | 0.73±0.21   | 1.68±0.61    | 2.13±0.65    |
|               | LPS                     | 3.79±0.84   | 9.14±1.79    | 23.03±12.74**|
|               | Q-VD-OPh                | 0.82±0.31   | 2.25±0.64    | 2.57±0.81    |
|               | Q-VD-OPh + LPS          | 3.46±0.65   | 6.34±0.52    | 15.87±5.38   |
|               | Caspase-6 KO control    | 0.30±0.05   | 1.19±0.25    | 1.31±0.22    |
|               | Caspase-6 KO LPS        | 2.44±0.44   | 5.28±0.81    | 15.28±7.12**|
| **IL-1β**     | Control                 | 10.27±2.35  | 36.66±10.08  | 51.40±10.28  |
|               | LPS                     | 108.91±18.43*** | 214.48±15.81**** | 255.88±21.37**** |
|               | Q-VD-OPh                | 19.02±5.53  | 57.40±15.02  | 70.89±10.94  |
|               | Q-VD-OPh + LPS          | 111.49±13.12*** | 195.42±20.04**** | 229.66±27.64**** |
|               | Caspase-6 KO control    | ND<         | 16.48±4.48   | 24.57±6.84   |
|               | Caspase-6 KO LPS        | 70.70±22.13 | 145.15±44.89* | 195.92±39.78** |
| **IL-2**      | Control                 | ND<         | ND<          | ND<          |
|               | LPS                     | 3.72±1.51   | 5.86±1.33    | 6.63±1.77    |
|               | Q-VD-OPh                | ND<         | ND<          | 2.11±0.92    |
|               | Q-VD-OPh + LPS          | 3.90±1.63   | 5.21±1.53    | 7.15±2.23    |
|               | Caspase-6 KO control    | ND<         | ND<          | ND<          |
|               | Caspase-6 KO LPS        | 1.96±0.53   | 2.46±0.90    | 4.56±1.61    |
| **IL-3**      | Control                 | 0.33±0.08   | 0.57±0.13    | 1.01±0.13    |
|               | LPS                     | 1.66±0.41   | 4.27±1.19*** | 5.06±0.99*** |
|               | Q-VD-OPh                | 0.26±0.04   | 0.97±0.16    | 1.26±0.17    |
|               | Q-VD-OPh + LPS          | 1.75±0.38   | 3.18±0.70*   | 4.14±0.86**  |
|               | Caspase-6 KO control    | 0.15±0.03   | 0.43±0.17    | 0.54±0.17    |
|               | Caspase-6 KO LPS        | 1.13±0.43   | 2.46±0.90    | 4.92±1.84**  |
| **IL-4**      | Control                 | 0.70±0.19   | 1.49±0.50    | 1.93±0.60    |
|               | LPS                     | 3.24±0.93   | 7.45±2.06*** | 8.70±1.74*** |
|               | Q-VD-OPh                | 0.96±0.29   | 1.99±0.60    | 2.51±0.83    |
|               | Q-VD-OPh + LPS          | 2.97±0.61   | 5.81±1.15*   | 7.93±1.60*** |
|               | Caspase-6 KO control    | 0.69±0.05   | 1.43±0.21    | 1.65±0.17    |
|               | Caspase-6 KO LPS        | 2.64±0.48   | 5.24±0.67*   | 8.21±2.14**  |
| **IL-5**      | Control                 | 0.10±0.02   | 0.22±0.06    | 0.33±0.09    |
|               | LPS                     | 0.61±0.11   | 1.68±0.36**** | 1.87±0.35**** |
|               | Q-VD-OPh                | 0.24±0.07   | 0.34±0.07    | 0.41±0.08    |
|               | Q-VD-OPh + LPS          | 0.53±0.16   | 1.17±0.23**  | 1.57±0.27**  |
|               | Caspase-6 KO control    | ND<         | ND<          | 0.32±0.07    |
|               | Caspase-6 KO LPS        | 0.56±0.16   | 1.34±0.43    | 1.89±0.54*   |
| **IL-9**      | Control                 | ND<         | ND<          | ND<          |
|               | LPS                     | 41.10±9.15  | 71.43±15.68  | 82.51±10.33  |
|               | Q-VD-OPh                | ND<         | 17.58±3.22   | 15.33±3.45   |
|               | Q-VD-OPh + LPS          | 34.44±3.69  | 54.00±4.33   | 70.77±6.21   |
|               | Caspase-6 KO control    | ND<         | ND<          | ND<          |
|               | Caspase-6 KO LPS        | 0.56±0.16   | 1.34±0.43    | 1.89±0.54*   |
| **IL-10**     | Control                 | 1.73±0.51   | 4.62±1.52    | 8.08±1.44    |
|               | LPS                     | 14.83±2.68* | 32.91±4.05**** | 44.13±5.43**** |
|               | Q-VD-OPh                | 2.33±0.78   | 7.30±1.08    | 8.90±2.21    |
|               | Q-VD-OPh + LPS          | 14.63±2.29* | 29.94±4.90**** | 39.27±4.84**** |
|               | Caspase-6 KO control    | 0.82±0.29   | 3.57±0.81    | 5.39±1.41    |
|               | Caspase-6 KO LPS        | 11.19±3.55  | 24.38±9.03*  | 33.13±8.72** |
| **IL-12p70**  | Control                 | 2.62±0.52   | 15.25±3.85   | 16.95±5.72   |
|               | LPS                     | 37.28±8.98  | 102.00±19.80**** | 113.84±15.63**** |
|               | Q-VD-OPh                | 11.91±4.15  | 16.4±4.68    | 23.56±8.44   |
|               | Q-VD-OPh + LPS          | 37.29±3.56  | 76.69±7.19**** | 101.98±7.91**** |
|               | Caspase-6 KO control    | ND<         | ND<          | 5.37±1.31    |
|               | Caspase-6 KO LPS        | 20.02±5.65  | 54.23±15.19  | 105.16±42.36 |
### Table 2. (continued)

| Analyte       | Treatment       | 6 h          | 24 h          | 48 h          |
|---------------|-----------------|--------------|--------------|--------------|
| IL-13         | Control         | ND<          | 29.84±8.02   | 34.92±8.16   |
|               | LPS             | 97.17±31.48  | 173.48±40.41*| 232.22±50.95***|
|               | Q-VD-OPh        | ND<          | 51.07±19.78  | 57.49±12.22  |
|               | Q-VD-OPh + LPS  | 88.34±20.85  | 154.10±30.59*| 213.85±61.14**|
| Caspase-6 KO control | ND<             | 21.88±3.11   | 27.84±5.86   |
| Caspase-6 KO LPS  | 53.61±13.21    | 99.12±29.34  | 129.46±28.71**|
| IL-17 Control | LPS             | 0.26±0.05    | 0.83±0.19    | 1.03±0.25    |
|               | Q-VD-OPh        | 2.02±0.35    | 4.98±0.81****| 4.96±1.03****|
|               | Q-VD-OPh + LPS  | 0.48±0.23    | 0.99±0.17    | 1.67±0.55    |
| Caspase-6 KO control | ND<             | 1.95±0.24    | 3.81±0.24**  | 4.16±0.85**  |
| Caspase-6 KO LPS  | 1.56±0.41       | 2.73±0.75    | 4.49±1.54    |
| Eotaxin (CCL11)| Control        | ND<          | 84.41±14.12  | 105.22±30.39 |
|               | LPS             | 291.37±52.82 | 746.71±93.30**| 1,012.50±163.60***|
|               | Q-VD-OPh        | ND<          | 153.74±29.38 | 183.37±61.77 |
|               | Q-VD-OPh + LPS  | 278.22±56.34 | 649.69±137.88**| 857.23±171.55***|
| Caspase-6 KO control | ND<             | 44.52±8.49   | 44.56±9.57   |
| Caspase-6 KO LPS  | 57.53±12.27    | 98.93±10.39  | 146.41±42.58|
| GM-CSF Control | LPS             | 63.67±22.04  | 117.84±35.65 | 141.13±32.00|
|               | Q-VD-OPh        | ND<          | ND<          | ND<          |
|               | Q-VD-OPh + LPS  | 72.82±18.12  | 100.06±25.17 | 123.76±29.88|
| Caspase-6 KO control | ND<             | 44.52±8.49   | 44.56±9.57   |
| Caspase-6 KO LPS  | 57.53±12.27    | 98.93±10.39  | 146.41±42.58|
| IFN-γ Control  | LPS             | 7.94±3.45    | 16.70±4.43   | 21.18±4.85**|
|               | Q-VD-OPh        | ND<          | 5.77±2.53    | 3.80±1.26    |
|               | Q-VD-OPh + LPS  | 6.11±1.80    | 13.71±3.08   | 19.21±5.80**|
| Caspase-6 KO control | ND<             | ND<          | ND<          |
| Caspase-6 KO LPS  | 3.00±0.69       | 6.88±2.22    | 12.47±4.50   |
| MIP-1α Control | LPS             | 35.55±13.07  | 230.49±89.53 | 367.82±138.60|
|               | Q-VD-OPh        | 1,440.85±451.02 | 6,521.97±867.18 | >ND |
|               | Q-VD-OPh + LPS  | 78.39±31.86  | 373.96±98.12 | 738.50±260.24|
| Caspase-6 KO control | ND<             | 1,033.63±153.93 | 5,705.81±949.03 | >ND |
| Caspase-6 KO LPS  | 42.06±3.61      | 133.82±20.33 | 209.50±39.70|
| MIP-1β Control  | LPS             | 73.77±33.28  | 738.32±312.24 | 1,358.61±572.17|
|               | Q-VD-OPh        | 1,583.73±478.34 | 10,586.11±6,792.96* | 8,525.95±2,119.06*|
|               | Q-VD-OPh + LPS  | 78.39±31.86  | 373.96±98.12 | 738.50±260.24|
| Caspase-6 KO control | ND<             | 1,033.63±153.93 | 5,705.81±949.03 | >ND |
| Caspase-6 KO LPS  | 697.56±265.09   | 2,065.97±956.10* | 3,307.88±1,301.69***|
| RANTES Control  | LPS             | 73.77±33.28  | 738.32±312.24 | 1,358.61±572.17|
|               | Q-VD-OPh        | 1,583.73±478.34 | 10,586.11±6,792.96* | 8,525.95±2,119.06*|
|               | Q-VD-OPh + LPS  | 78.39±31.86  | 373.96±98.12 | 738.50±260.24|
| Caspase-6 KO control | ND<             | 1,033.63±153.93 | 5,705.81±949.03 | >ND |
| Caspase-6 KO LPS  | 1,140.15±421.87 | 4,278.15±2,320.81 | 7,043.62±2,438.00*|

Cytokine and chemokine production (pg/ml) analysed from microglia cell supernatants collected at 6, 24 and 48 h from WT control, WT LPS, WT Q-VD-OPh, WT Q-VD-OPh + LPS, caspase-6 KO control, and caspase-6 KO LPS treated cells. Data were analysed with a two-way ANOVA (for time and treatment) and, when significant, a Dunnett’s post hoc analysis was conducted comparing WT control with WT LPS, WT Q-VD-OPh and WT Q-VD-OPh + LPS, or a Sidak post hoc analysis was carried out comparing caspase-6 KO control and caspase-6 KO LPS. ND<: values were below detectable range, >ND: values were above detectable range. Data are expressed as means ± SEM (n = minimum of 5 independent experiments). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Microglial Activation

Cell supernatants were analysed using a 23-plex mouse cytokine panel. No differences were observed between WT control, WT Q-VD-OPh and caspase-6 KO control groups (table 2). LPS treatment resulted in increased expression of most of the cytokines analysed: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-9, IL-10, IL-12p70, IL-13, IL-17, CCL11 (eotaxin), GM-CSF, IFN-γ, CCL3 (MIP-1α), CCL4 (MIP-1β), CCL2 (MCP-1) and CCL5 (RANTES; table 2). Inhibition of caspase activity by Q-VD-OPh or
deletion of the caspase-6 gene in microglia did not significantly influence the LPS-induced changes of IL-6, IL-12p40, G-CSF, KC, MCP-1, and TNF-α (fig. 4).

Microglial Phenotype

In a previous study, Chhor et al. [37] detailed microglial phenotype markers, of which we chose six representing M1 (classical) cytotoxic (COX-2 and iNOS; fig. 5A, B), M2a tissue repair (CD206 and IGF-1; fig. 5C, D) and M2b immunosuppressive (IL-1ra and SOCS3; fig. 5E, F) phenotypes. Gene expression of microglial phenotype markers was assessed in LPS-treated caspase-6 KO microglia or WT microglia ± Q-VD-OPh at 6, 24 and 48 h (fig. 5). Interestingly, SOCS3 gene expression (fig. 5F) showed a significant time (p < 0.05), treatment (p < 0.0001) and interaction (p < 0.01) effect. Post hoc analysis also revealed that caspase-6 KO microglia stimulated with LPS showed a different temporal expression compared with LPS-treated WT cells.
peaking significantly earlier at 6 h and being significantly lower than WT LPS treatment at 48 h. For WT control, WT Q-VD-OPh and caspase-6 KO control cells, gene expression for iNOS was not detected; therefore, data were normalised to WT LPS treatment for each time point.

**Discussion**

In the present study we examined the expression and possible role of caspase-6 in the immature brain after hypoxia-ischaemia and in primary microglia exposed to LPS. cl-C6 was present but expressed at a low level in a human post-mortem case of preterm white matter injury. In a rat model of hypoxia-ischaemia, caspase-6 expression was low and primarily evident in white matter at later time points compared with cl-C3, which is robustly expressed in the immature brain. Caspase-6 gene deletion did not affect the extent of brain injury following mild (50 min) or severe (60 min) hypoxia-ischaemia. However, we found that cl-C6 was present predominantly in activated microglia at 72 h following hypoxia-ischaemia. Previous studies have shown that administration of a broad-spectrum caspase inhibitor, Q-VD-OPh, offers neuroprotection following hypoxia-ischaemia and, therefore, we explored possible deleterious functions of caspases in primary microglia. We report subtle changes in the activation state of caspase-6 and other caspase family members and alterations in the production of cytokines in microglia following low-dose LPS stimulation.

The cellular expression of cl-C6 observed by us in the human preterm brain in the presence of white matter injury may highlight a subtle role for caspase-6 in the development of secondary [38] and tertiary brain injury [39]. Caspase-6 is traditionally described as an effector caspase and has recently been implicated in the process of axonal degeneration during neuronal apoptosis in ageing [14, 40]. The activation of caspase-6 has been shown to be regulated by caspase-1 [41], caspase-3/7 [14, 42] and caspase-9 [19], and caspase-6 itself can undergo self-activation [43]. Caspase-6 can also activate caspase-3 and caspase-8 [13, 44, 45], suggesting a more complicated function than first detailed.

Consistent with our findings in the human tissue, we also observed cl-C6 staining at 72 h following hypoxia-ischaemia in cell bodies and cell processes of white matter in the immature brain. This is in contrast with the adult brain following ischaemia-reperfusion (medial cerebral artery occlusion), where cl-C6 was present from 12 to 72 h in the cell body and processes of neurons [19]. Whilst the models of ischaemia result in different injury patterns, the delayed activation of caspase-6 seen in the immature brain may be representative of both low pro-caspase-6 expression seen in fetal human tissue [15] and high caspase-3 expression. It has been reported that caspase-3 is required to activate caspase-6 [14], and we propose that the presence of cl-C6 at 72 h following hypoxia-ischaemia (fig. 1) may be the downstream effect of caspase-3 activity which peaks at 24 h following hypoxia-ischaemia [33]. We did attempt to optimise and assess caspase-6 activity (substrate Ac-Val-Glu-Ile-Asp-AMC) in brain homogenates following hypoxia-ischaemia but were unsuccessful. Cleavage of lamin A/C has also been shown to be a specific indicator of caspase-6 activity [46], but we were unable to detect it in our samples as lamin A/C expression is only present in a minority of cells at P5 and P10 and in most cells at P15 in the mouse [47].

Our findings strongly indicate that in the immature brain caspase-3 is the most significant effector caspase – important in both brain development and apoptosis following hypoxia-ischaemia. This is in comparison with caspase-6, which appears to be an ‘age-dependent’ caspase, increasing expression and function during ageing [18]. This is further strengthened by our result that genetic deletion of caspase-6 was not protective in our neonatal model of hypoxia-ischaemia. It has been reported that neurons from caspase-6 knockouts are protected from excitotoxic injury, and as caspase-6 knockout mice age they have larger cortical and striatal volumes and develop learning deficits [48]. Akpan et al. [19] also found that caspase-6 knockout mice were protected from transient middle cerebral artery occlusion, retaining more neurons. However, all of these assessments have been performed in mice from the age of 2 months and onwards. Therefore, the functional role of cl-C6 remains to be elucidated in the immature brain. The fibrous staining we observed in the preterm brain and 72 h following hypoxia-ischaemia could indicate the initiation of fine axonal pruning and degeneration. Cusack et al. [49] have recently found that caspase-6-dependent and -independent pathways degenerate axons, and this is reliant on whether cells have experienced axon-specific (pruning) or whole cell apoptosis. This finding remains to be investigated further in our tissue by assessing later time points. Importantly, we observed cl-C6 co-localisation with amoeboid microglia in white matter following hypoxia-ischaemia. These cells were not of apoptotic morphology, and hence we decided to investigate the possible non-apoptotic role of caspase-6 in LPS-stimulated primary microglia. Microglia are the resident phagocytic cells of
the brain that are required during brain development and following tissue injury. Their involvement during neuronal apoptosis may suggest an interaction between apoptotic cues such as caspase activation and microglial activation.

We showed that the mRNA of a number of caspases was modulated following low-dose LPS stimulation (10 ng/ml), but caspase activity (using LETD, DEVD, VEID substrates) was not affected by LPS. Our findings are consistent with Kobayashi et al. [50], who also found that LPS did not induce or require caspase-6 activity in THP-1 macrophages. Burguillos et al. [24] have shown that caspase-3/7 and caspase-8 signalling can mediate microglial activation. Therefore, for comparison with caspase-6 knockout microglia, we also treated cells with Q-VD-OPh, a broad-spectrum caspase inhibitor that has been shown to be neuroprotective in neonatal models of hypoxia-ischaemia [9–11]. Q-VD-OPh targets caspases-1, -2, -3, -6, -8, -9, and -10. It effectively prevents apoptosis and, importantly, has a high potency at low concentrations and is non-toxic even at high concentrations [51, 52]. Whilst neuroprotective properties of Q-VD-OPh are primarily based on its anti-apoptotic function, the possible non-apoptotic effect Q-VD-OPh has on cell types such as microglia has not be investigated.

Microglia have both beneficial and detrimental actions. To better understand their function, the description of microglia phenotype or activation states has been sub-classified in classical activation (M1: pro-inflammatory cytokine production), alternate activation (M2a: anti-inflammatory cytokine production) and acquired deactivation (M2b – immunosuppressive). Chhor et al. [37] have described temporal changes in phenotype markers, from which we chose six markers that best represent each activation state. We found that caspase-6 knockout microglia displayed a different temporal expression of the M2b marker SOCS3 (suppressor of cytokine signalling), with an earlier maximum expression at 6 h compared with WT LPS microglia where SOCS3 expression peaked at 48 h following stimulation. The possible impact this may have on the microglia response remains to be elucidated. The M1 or M2a microglial phenotype markers were not significantly affected by caspase-6 gene deletion or by Q-VD-OPh.

Q-VD-OPh and caspase-6 gene deletion did not affect the production of cytokines in activated microglia. This is in contrast to Burguillos et al. [24], where caspase-3 and caspase-8 inhibition administered 1 h prior to high-dose LPS (100 ng/ml) resulted in a reduction of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12, IFN-γ). Caspase-6 knockout mice are reported to have a reduction in adult pulmonary macrophage production of TNF-α [50], but we did not observe this in our caspase-6 knockout primary microglial preparations. Interestingly, microglial cells treated with recombinant caspase-6 enhanced the production of TNF-α [25] and regulated synaptic plasticity and inflammatory pain, suggesting an interaction between caspase-6 and TNF-α that requires further investigation. Whilst the differences we observed following caspase inhibition and caspase-6 gene deletion were subtle, methodological considerations such as time of inhibitor administration, higher doses of LPS stimulation and choice of different stimulants which can polarise microglia into different phenotypes may yield different results.

In summary, we found that the contribution of caspase-6 to the development of acute injury in neonatal hypoxia-ischaemia is subtle and likely to be predominantly regulated by caspase-3 as well as upstream caspase-9, -2 and -8 [2–4, 6, 8, 12]. However, we found unique temporal regulation of caspase-6 activation in microglia, suggesting that caspase-6 may have a role in subsequent injury progression. Further studies are required in order to determine the role of caspase-6 at later time points.

Acknowledgements

We thank the Medical Research Council UK for the use of human tissue samples. We would also like to thank Anna-Lena Leverin for her expert technical assistance. The work was supported by the Swedish Medical Research Council (VR 2012-3500; H.H.), the Wilhelm and Martina Lundgren Foundation (H.H. and A.B.), the Åhlén Foundation (H.H.), the Frimurare Barnhus Foundation (H.H.), the Byggmästare Olle Engqvist Foundation, the Brain Foundation (2013-0035; H.H.), Governmental Grants for University Hospitals in Sweden (ALFGBG-137601; H.H.), the Wellcome Trust (WT094823; H.H.), and the Leducq Foundation (H.H.). The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s and St. Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust.

References

1. Soane L, Siegel ZT, Schuh RA, Fiskum G: Postnatal developmental regulation of Bcl-2 family proteins in brain mitochondria. J Neurosci Res 2008;86:1267–1276.
2. Hagberg H, Mallard C, Rouset CI, Thornton C: Mitochondria: hub of injury responses in the developing brain. Lancet Neurol 2014;13: 217–232.
3. Blomgren K, Hagberg H: Free radicals, mitochondria, and hypoxia-ischemia in the developing brain. Free Rad Biol Med 2006;40:388–397.
Taylor DL, Edwards AD, Mehmet H: Oxidative metabolism, apoposis and perinatal brain injury. Brain Pathol 1999;9:93–117.

Troy CM, Akpan N, Jean YY: Regulation of caspases in the nervous system implications for functions in health and disease. Prog Mol Biol Trans Sci 2011;99:265–305.

Zhu C, Wang X, Xu F, Bahr BA, Shibata M, Uchiyama Y, Hagberg H, Blomgren K: The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ 2005;12:162–176.

Wang X, Carlsson Y, Basso E, Zhu C, Rousset CI, Rasola A, Johansson BR, Blomgren K, Mallard C, Bernardi P, Forte MA, Hagberg H: Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J Neurosci 2009;29:2588–2596.

Carlsson Y, Schwendimann L, Vontell R, Rousset CI, Was J, LeBlanc A: Caspase-6 activity in human apoptotic and excitotoxic neonatal brain injury. Annu Neurol 2011;70:781–789.

Han W, Sun Y, Wang X, Zhu C, Blomgren K: Delayed, long-term administration of the caspase inhibitor Q-VD-OPh reduces brain injury induced by neonatal hypoxia-ischemia. Dev Neurosci 2014;36:64–72.

Chauvier D, Renolleau S, Basso E, Zhu C, Rousset CI, Rasola A, Johansson BR, Blomgren K, Mallard C, Bernardi P, Forte MA, Hagberg H: Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J Neurosci 2009;29:2588–2596.

Zhu C, Wang X, Huang Z, Qiu L, Xu F, Vahsen N, Nilsson M, Eriksson PS, Hagberg H, Cullmsee C, Plesnila N, Kroemer G, Blomgren K: Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ 2007;14:775–784.

Renolleau S, Fau S, Goyenvalle C, Joly LM, Chauvier D, Jacotot E, Mariani J, Chariaut-Marlangue C, Supramaniam V, Hagberg H, Gressens P, Jacotot E: Genetic inhibition of caspase-2 reduces hypoxic-ischemic and excitotoxic neonatal brain injury. Annu Neurol 2011;70:781–789.

Chauvier D, Renolleau S, Hofinanjanaisa S, Ankri S, Bezaud M, Schwendimann L, Rousset CI, Casimir R, Hoebecq J, Smirnova M, Deeg H, Trichet AP, Carlsson Y, Wang X, Berse T, Bassnett S: Role of the executioner caspases in cerebral palsy? Lancet Neurol 2012;11:556–561.

Vontell R, Supramaniam V, Thornton C, Wyatt-Ashmead J, Mallard C, Gressens P, Ruth-erford M, Hagberg H: Toll-like receptor 3 expression in glia and neurons alters in response to white matter injury in preterm infants. Dev Neurosci 2013;35:130–139.

Svedin P, Hagberg H, Savman Y, Zhu C, Mallard C: Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007;27:1511–1518.

Jean DM, Wang X, Kaindl AM, Gressens P, Fleiss B, Hagberg H, Mallard C: Microglial MYD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro. Brain Behav Immun 2010;24:776–783.

Wang X, Carlsson JO, Zhu C, Bahr BA, Hagberg H, Blomgren K: Caspase-3 activation after neonatal rat cerebral hypoxia-ischemia. Biol Neonate 2001;79:172–179.

McGee GP, Spence J: Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ 2008;15:322–331.

Benkova B, Lozanov V, Ivanov IP, Mitev V: Evaluation of recombinant caspase specificity by competitive substrates. Anal Biochem 2009;384:68–74.

Pereira NA, Song Z: Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 2008;377:873–877.

Chhor V, Le Charpentier T, Lebón S, Ore MV, Celador IL, Jossand J, Degos V, Jactot E, Hagberg H, Savman K, Mallard C, Gressens P, Fleiss B: Characterization of phenotype markers and neurotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 2013;32:70–85.

Thornton C, Rousset CI, Kichev A, Miyakuni Y, Vontell R, Baburamani AA, Fleiss B, Gressens P, Hagberg H: Molecular mechanisms of neonatal brain injury. Neurol Res Int 2012;2012:56320.

Fleiss B, Gressens P: Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol 2012;11:556–566.

Nikolaev A, McLaughlin T, O’Leary DD, Tesser-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981–989.

Guo H, Petrini D, Zhang Y, Bergeron C, Goodyer CG, LeBlanc AC: Caspase-3 activation in human apoptotic neurons. Cell Death Differ 2006;13:285–292.

Inoue S, Browne G, Melino G, Cohen GM: Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 2009;16:1053–1061.

Klaiman G, Champagne N, LeBlanc AC: Self-activation of caspase-6 in vitro and in vivo: caspase-6 activation does not induce cell death in HEK293T cells. Biochem Biophys Acta 2009;1793:592–601.
Does Caspase-6 Have a Role in Perinatal Brain Injury?

44 Cowling V, Downward J: Caspase-6 is the direct activator of caspase-8 in the cytochrome C-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002;9:1046–1056.

45 Monnier PP, D’Onofrio PM, Magharious M, Hollander AC, Tassew N, Szydlowska K, Tymianski M, Koeberle PD: Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. J Neurosci 2011;31:10494–10505.

46 Mintzer R, Ramaswamy S, Shah K, Hannoush RN, Pozniak CD, Cohen F, Zhao X, Plise E, Lewcock JW, Heise CE: A whole cell assay to measure caspase-6 activity by detecting cleavage of lamin A/C. PLoS One 2012;7:e30376.

47 Rober RA, Weber K, Osborn M: Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 1989;105:365–378.

48 Uribe V, Wong RK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, Ehrnhoefer DE, Vaid K, Miller FD, Deshmukh M, Howland D, Hayden MR: Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet 2012;21:1954–1967.

49 Cusack CL, Swahari V, Hampton Henley W, Michael Ramsey J, Deshmukh M: Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning. Nat Commun 2013;4:1876.

50 Kobayashi H, Nolan A, Naveed B, Hoshino Y, Segal LN, Fujita Y, Rom WN, Weiden MD: Neutrophils activate alveolar macrophages by producing caspase-6-mediated cleavage of IL-1 receptor-associated kinase-M. J Immunol 2011;186:403–410.

51 Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL: Q-VD-OPh, a broad-spectrum caspase inhibitor with potent anti-apoptotic properties. Apoptosis 2003;8:345–352.

52 Chauvier D, Ankri S, Charriaut-Marlangue C, Casimir R, Jacotot E: Broad-spectrum caspase inhibitors: from myth to reality? Cell Death Differ 2007;14:387–391.